Merck and Daiichi withdraw US filing for lung cancer ADC
Merck & Co (MRK) and Daiichi Sankyo (4568) withdrew their US approval application for I-DXd, a lung cancer treatment, after FDA feedback. The drug targets extensive-stage small-cell lung cancer post-chemotherapy.
How this was made
The 30-second read
Why it matters
Regulatory feedback led to a voluntary withdrawal, signaling that the FDA found issues with the submission.
Market read
The withdrawal removes a near‑term growth catalyst for Merck, likely prompting a short‑term price decline.
What to watch
The decision may free resources for other pipeline candidates, mitigating the short‑term hit.
Background
Merck & Co and Daiichi Sankyo had been seeking accelerated approval for ifinatamab deruxtecan (I‑DXd) for extensive‑stage small‑cell lung cancer.
Ticker impact
Merck withdrew its FDA accelerated approval filing for the lung cancer ADC, indicating a setback for the drug's US launch.
likely downward pressure as investors price in the lost approval timeline
Regulatory setbacks for a late‑stage oncology asset are material and often lead to immediate stock declines.
Market effects
Potential ripple effect on other oncology ADC developers as investors reassess regulatory risk.
US biotech sector may see modest pullback amid heightened FDA scrutiny.
Limited to Merck and its partners; no broad market impact.
Counterpoint
If the withdrawal is strategic to pursue a better data package, the long‑term upside could remain intact.
Key entities
- CompanyMerck & Co
US pharmaceutical giant, ticker MRK.
- CompanyDaiichi Sankyo
Japanese drugmaker, ticker 4568 on TSE.
